Alnylam Pharmaceuticals
ALNY
#575
Rank
A$56.62 B
Marketcap
$439.03
Share price
-2.11%
Change (1 day)
65.02%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.06

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$6.65. In 2022 the company made an earnings per share (EPS) of -$15.03 a decrease over its 2021 EPS that were of -$11.65.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.06-59.72%
2022-$15.0329.03%
2021-$11.65-3.36%
2020-$12.06-8.48%
2019-$13.177.67%
2018-$12.2339.74%
2017-$8.7512.94%
2016-$7.7538.84%
2015-$5.58-32.88%
2014-$8.32259.44%
2013-$2.31-31.25%
2012-$3.3752.94%
2011-$2.2030.77%
2010-$1.68-8.77%
2009-$1.8478.13%
2008-$1.04-70.78%
2007-$3.5499.09%
2006-$1.78-43.88%
2005-$3.17-82.33%
2004-$17.95-59.23%
2003-$44.03

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.75-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$60.46-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$12.67 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.44-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.73-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.05-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.15-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.24-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel